2023
Intravenous iron for treatment of iron deficiency anemia during pregnancy and associated maternal outcomes
Burn M, Lundsberg L, Culhane J, Partridge C, Son M. Intravenous iron for treatment of iron deficiency anemia during pregnancy and associated maternal outcomes. The Journal Of Maternal-Fetal & Neonatal Medicine 2023, 36: 2192855. PMID: 36958808, DOI: 10.1080/14767058.2023.2192855.Peer-Reviewed Original ResearchConceptsIron deficiency anemiaMaternal morbidity compositeIntravenous ironMorbidity compositePotential confoundersElectronic medical recordsPregnant patientsTreatment courseDeficiency anemiaHigh-risk baseline characteristicsMultivariable logistic regression modellingRetrospective cohort studyFull treatment courseHospital electronic medical recordsIntensive care unitLogistic regression modellingGreater increaseMaternal morbidityMaternal outcomesNeonatal outcomesBaseline characteristicsCohort studyBlood transfusionPrimary outcomeTerm delivery
2020
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. JAMA 2020, 323: 432-443. PMID: 32016310, PMCID: PMC7042864, DOI: 10.1001/jama.2019.22450.Peer-Reviewed Original ResearchConceptsIron deficiency anemiaFerric carboxymaltoseIncidence of hypophosphatemiaIron isomaltosideDay 0Oral ironBone homeostasisCommon adverse drug reactionsFibroblast growth factor 23Trial ABiomarkers of mineralIntravenous iron isomaltosideRisk of hypophosphatemiaPrimary end pointReduced kidney functionGrowth factor 23Adverse drug reactionsIntravenous ironSerum phosphateFactor 23Kidney functionParathyroid hormoneRandomized trialsClinic sitesDrug reactions
2004
Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients
Perazella M, Brewster U, Perazella M. Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients. Seminars In Dialysis 2004, 17: 57-60. PMID: 14717813, DOI: 10.1111/j.1525-139x.2004.17115.x.BooksConceptsInnate immune responseRisk of infectionIntravenous ironEnd-stage renal disease patientsHost innate immune responseRenal disease patientsIron-deficient patientsAdministration of ironOral ironIron therapyMost patientsHemodialysis patientsActive infectionDisease patientsIron preparationsIron overloadAllergic reactionsClinical studiesImmune responsePatientsBacterial infectionsIron deficiencyInfectionRiskBacterial growth
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply